We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Histology Expression Predictor Assay Eliminates Subjectivity from Lung Cancer Diagnostics

By LabMedica International staff writers
Posted on 29 Jul 2013
A gene expression-based predictor assay for lung cancer FFPE (formalin-fixed, paraffin-embedded) specimens was able to identify a variety of cancers with accuracy and precision similar to that of microscopic examination by pathologists. More...


FFPE tissues are the most widely available specimens for retrospective clinical studies of disease mechanisms. These archived materials provide a valuable source of stable nucleic acids for gene expression analysis, using real-time quantitative reverse transcription-PCR (qRT-PCR) or microarray analysis. As the use of PCR technology has become more prevalent in molecular testing, it has enhanced the clinical utility of FFPE tissues. However, the recovery of quality RNA from FFPE specimens is often problematic, as the fixation process causes cross-linkage between nucleic acids and proteins, and covalently modifies RNA by the addition of monomethyl groups to the bases. As a result, the molecules are rigid and susceptible to mechanical shearing, and the cross-links may compromise the use of RNA as a substrate for reverse transcription. Therefore, in order to utilize FFPE tissues as a source for gene expression analysis, a reliable method is required for extraction of RNA from the cross-linked matrix.

Lung cancer histologic diagnosis is clinically relevant because there are treatment indications and contraindications that are histology-specific. In practice, histologic diagnosis can be challenging depending on the success of sampling and on various tumor characteristics. In addition, the subjective nature of microscopic examination can lead to disagreements among pathologists reviewing the same specimens. Investigators at the University of North Carolina (Chapel Hill, USA) and the University of Utah (Salt Lake City, USA) hope to have solved some of these problems by developing a gene expression-based predictor of lung cancer histology for FFPE specimens.

Genes predictive of lung cancer histologies were derived from published cohorts that had been profiled by microarrays. Expression of these genes was measured by RT-qPCR in FFPE samples from a cohort of 442 lung cancer patients. A histology expression predictor (HEP) was developed using RT-qPCR expression data for adenocarcinoma, carcinoid, small cell carcinoma, and squamous cell carcinoma.

In cross-validation, the HEP exhibited mean accuracy of 84%. The HEP was compared with pathologist diagnoses on the same tumor block specimens, and the HEP yielded accuracy and precision similar to the pathologists.

"Our predictor identifies the major histologic types of lung cancer in paraffin-embedded tissue specimens, which is immediately useful in confirming the histologic diagnosis in difficult tissue biopsy specimens," said contributing author Dr. Neil Hayes, associate professor of medicine at the University of North Carolina. "As we learn more about the genetics of lung cancer, we can use that understanding to tailor therapies to the individual's tumor. Gene expression profiling has great potential for improving the accuracy of the histologic diagnosis. Historically, gene expression analysis has required fresh tumor tissue that is usually not possible in routine clinical care. We desperately needed to extend the analysis of genes (aka RNA) to paraffin samples that are routinely generated in clinical care, rather than fresh frozen tissue. That is the major accomplishment of the current study and one of the first large scale endeavors in lung cancer to show this is possible."

A detailed description of the histology expression-predictor assay was published in the July 2013 issue of the Journal of Molecular Diagnostics.

Related Links:
University of North Carolina
University of Utah



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.